Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
JAMA Oncology|March 13, 2020
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical TrialEsther Pohl-Rescigno, Jan Hauke, Sibylle Loibl, et al.
Cancers|July 9, 2022
Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian CancerMuriel Rolfes, Julika Borde, Kathrin Möllenhoff, et al.
JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
JAMA Oncology|December 30, 2016
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast CancerGuido Neidhardt, Jan Hauke, Juliane Ramser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA StudyPeter A Fasching, Sabine Schmatloch, Jan Hauke, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 25, 2017
Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragilityIrene Catucci, Ana Osorio, Brita Arver, et al.
Human Mutation|December 8, 2017
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practiceGillian Ellison, Miika Ahdesmäki, Sally Luke, et al.
BMC Cancer|March 9, 2018
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historyChristoph Engel, Kerstin Rhiem, Eric Hahnen, et al.
JAMA Oncology|July 18, 2017
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical TrialEric Hahnen, Bianca Lederer, Jan Hauke, et al.
Breast Cancer Research : BCR|May 1, 2019
Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancerNana Weber-Lassalle, Julika Borde, Konstantin Weber-Lassalle, et al.
Pageof 8